BIOTECH INVE$T
 

Biotech Inve$t, 2019年3月19日(二)

08:45

Organiser’s welcome Remarks

Joe Zhou
08:50

Chair’s opening Remarks

Joe Zhou, Chief Executive Officer, Genor BioPharma, Walvax Group

Opening Keynote Plenary

David Lane
09:00

Going global and keeping it local: Is biotech innovation sustainable in Asia?

In this keynote presentation, Sir David Lane, one of the key scientists credited on the discovery of cancer gene p53, a gene which mutation cause near 50% of all human cancer, will share his view on how biomedical sciences have developed in Singapore, Japan and the remaining APAC region, and prospects for Asian biotech and pharma industry.
David Lane, Chief Scientist, Agency for Science, Technology and Research (A*STAR)
Byung-Geon Rhee
09:20

Looking east: Integrating Asia into the global era of innovative medicine

Byung-Geon Rhee, Chief Executive Officer, SCM Lifescience
Panel discussion
09:40

Pharma Trends: Women health as the next focus

Women’s health goes beyond mother & childcare. For instance, women has a higher risk of cardiovascular diseases compared to men, hence there is a need to invest more on addressing the biological differences in mainstream disease studies to ensure a more effective, personalised treatment. In addition, big data & AI application on female subjects may also differ from male subjects, prompting a need to investigate how studies should be developed differently in the future. This panel brings experts to debate and discuss how femtech is shaping to be the next global pharma focus and the new areas of focus in women's healthcare.
Moderator: Reenita Das, Partner, Frost & Sullivan
Evelyn Pang, Head Of Operations, Sanofi Pasteur
Marcel Van Duin, VP Research, Therapeutic Area Head, Reproductive Medicine & Women's Health, Ferring Pharmaceuticals
10:20

Speed networking & Networking Refreshment

Carrie Hillyard
Biotech Inve$t
11:15

Chair's opening remarks

Carrie Hillyard, Chairman, FitGenes
Panel discussion
Biotech Inve$t
11:20

Medtech, Diagnostics, Wearables- What are the next trends in biotech investment landscape?

Moderator: Joseph Mocanu, Managing Director, Verge Capital Management
Mario Gattino, Chief Executive Officer, Respiri
Dean Ho, Co-Founder, KYAN Therapeutics
Ashish Patel, Head Of Research, Investment Manager, Mercia Technologies
Petcha Kucha
Biotech Inve$t
12:00

Biotech Pitch

10 minutes per company
William Jia, Chief Scientific Officer, Virogin Biotech
Ken Taylor, Chief Executive Officer, Living Cell Technologies Limited
Poh Loong Soong, Co-Founder, Ternion Biosciences Pte. Ltd
Vishal Doshi, Chief Executive Officer, AUM Biosciences
George Kopsidas, Executive Director, Imunexus
12:40

Exhibition Visit & Networking Lunch

Biotech Inve$t
14:10

Chair’s opening remarks

Panel discussion
Biotech Inve$t
14:20

Investor perspectives: Accessing capital for scaling up your biotech

Moderator: Henry Ines, Chief Executive Officer, Shivom.io
Haolin Sung, Director, Direct Investment, Diamond BioFund
Chongdeok Park, Chief Development Officer, Kolon Pharmaceuticals
Joseph Mocanu, Managing Director, Verge Capital Management
Petcha Kucha
Biotech Inve$t
14:45

Biotech Pitch

10 minutes per company
Liping Liu, Chief Executive Officer And Chief Scientific Officer, Shenzhen HighTide Biopharmaceutical Ltd.
Alexandre Civiere, Project Manager, CellProthera Pte Ltd
Sabrina Ng, Chief Financial Officer, Hummingbird Bioscience
15:40

Exhibition Visit & Networking Refreshments

Panel discussion
Biotech Inve$t
16:05

Leveraging larger capital pools: Let’s talk listings & capital markets

  • Global capital markets and opportunities
  • Biotech market readiness in APAC public listing
  • Hong Kong- the next Asia biotech capital destination?
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals
Abraham Cinta, Chief Executive Officer, ARC Capital
Billy Cho, Chief Financial Officer, Zai Laboratory
Nomura Hironoshin, Pharmaceuticals, Biotech, Otc And Small Companies, Mizuho Securities
Petcha Kucha
Biotech Inve$t
17:10

Biotech Pitch

10 minutes per company
Yi-Chun Maria Chen, Director Of Business Development, Immunwork Inc.
Nir Arbel, Co-Founder And Chief Executive Officer, Carmentix
Billy Cho, Chief Financial Officer, Zai Laboratory
Meng Chi Chen, Director Business Development, BRIM Biotechnology
17:40

Networking Cocktail & End of Conference Day 1

last published: 17/Jan/19 09:15

Biotech Inve$t, 2019年3月20日(三)

08:45

Organiser’s welcome Remarks

08:50

Chairman’s opening Remarks

Nadia Suttikulpanich
09:00

Disrupt before being disrupted: Using digital tech to connect to previously uneconomic chronic disease customers

Insurance is a tricky part of healthcare business. Increased healthcare costs lead to a higher profit for pharma and provider companies but burdens the government budget and hurts the insurance business. Since taking care of a chronic patient is a lifelong commitment, the availability of insurance to cover this essential treatment is often expensive and uneconomical. Join Nadia Suttikulpanich, Head of the Fuchsia Innovation Center, part of Muang Thai Life Assurance, Thailand as she shares how they are adopting digital tech to pilot chronic disease cover to provide for patients in need while keeping their insurance business profitable.
Nadia Suttikulpanich, Head Of Fuchsia Innovation Center For Muang Thai Life Assurance, Muang Thai Life Assurance Public Company
Edward Rosen
09:20

The path to personalised medicine: Key developments

Everyone knows the potential benefits of personalised medicine, but how do we get there? Finding and better defining disease through biomarkers and more accurate diagnostics. Targeted therapeutics to leverage new and emerging diagnostic capabilities. Personalized Medicine to Real-Time Medicine. How to drive success across industry and clinical implementation in an economic manner. This presentation discusses various strategies and key considerations to drive the symbiosis between academia, industry and clinical medicine to drive vastly improved patient outcomes.
Edward Rosen, Leader, Glendevon Life Sciences LLC & Executive in Residence, Columbia Technology Ventures
Panel discussion
09:40

Pharma 4:0 Digital disruption: New players, new opportunities

Moderator: Shwen Gwee, General Manager, Digital Accelerator (Global Drug Development), Novartis
Teck Jack Tan, Chairman And Medical Director, Northeast Medical Group
Matt Cooper, Business Development And Research Director, NIHR Clinical Research Network
Andreas Koester, Vice President Of Clinical Trial Innovation And External Alliances, Johnson & Johnson
David Benshoof Klein, Chief Executive Officer, Click Therapeutics
Raghu Bathina, Founder, Future World Studios
10:20

Roundtable discussion

Panel discussion
Biotech Inve$t
10:20

Attracting VC capital: What are investors looking for from early stage Asian biotechs?

Moderator: Mayank Gurnani, Associate Professor, Industry Liaison Office, National University of Singapore
Carrie Hillyard, Chairman, FitGenes
Hsien-Hui Tong, Head, Venture Investing, SGInnovate
Sinclair Dunlop, Managing Partner, Epidarex Capital
Alfred Scheidegger, Partner And Founder, Nextech Invest

Table 1 Working with clinical outsourcing partners: Risk management and prevention

Pei Yin Tan, Director, Asia Clinical Operations, Medicine Development Center, Eisai Clinical Research Singapore Pte Ltd

Table 2 Fostering commercial partnerships to tap on emerging APAC markets

Charles Stacey, President And Chief Executive Officer, Cerecin

Table 3 Regulatory collaboration and opportunities in more efficient drug development

Phusit Prakongsai, Ministry of Public Health Thailand

Table 4 Strategies in making drugs more affordable and accessible to patients in developing countries

Pratapa Satyanarayana, Former Senior Director And Group Country Head, Dr. Reddy?s Laboratories Ltd.

Table 5 Universal healthcare- Is it really costly?

Table 6 A convergent approach: Tapping on western expertise to serve Asia population

Philippe Pinton, Regional Head, Specialty Therapy, Takeda

Table 7 Precision to personalised medicine- How do we get there?

Mrunalini Jagtap, Data Management Lead, SICS, A*STAR

Table 8 Leveraging blockchain technology in making clinical trials more transparent and efficient

Table 9: Data Science in practice: How can sales reps and MSLs use Big Data?

Prabhuram Krishnan, South Asia Medical Director, Ipsen Pharma

Table 10: The Singapore biotech ecosystem - What comes after the Inflexion?

11:00

Exhibition Visit & Networking Refreshments

Petcha Kucha
Biotech Inve$t
11:00

Biotech Pitch

10 minutes per company
George Kopsidas, Executive Director, Imunexus
13:00

Exhibition Visit & Networking Lunch

Panel discussion
Biotech Inve$t
13:00

The Greater China Opportunity: Capital raising & partnerships

Moderator: Edward Rosen, Leader, Glendevon Life Sciences LLC & Executive in Residence, Columbia Technology Ventures
Sean Wuxiong Cao, Managing Director, C Bridge Capital
Donald Xu, Managing Director, Lynx Financial
Marietta Wu, Managing Partner, Quan Capital
Xichen Lin, Director Of Innovation Sourcing, Novo Nordisk
Jeffry Wu, Managing Director, Milestone Capital Management Ltd.
Petcha Kucha
Biotech Inve$t
13:40

Biotech Pitch

10 minutes per company
Ian Huen, Chief Executive Officer, Aptorum Group
Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbH
Mai Jing Liao, Co-Founder, Vice President For Business Development And Portfolio Management, Harbour Biomed
Panel discussion
Biotech Inve$t
14:50

Southeast Asia Focus: Fostering homegrown innovation and biotech firms Moderator:

Moderator: Shwen Gwee, General Manager, Digital Accelerator (Global Drug Development), Novartis
Xiangqian Lin, Managing Partner, Esco Ventures
Charles Stacey, President And Chief Executive Officer, Cerecin
Vishal Doshi, Chief Executive Officer, AUM Biosciences
Yuliana Indriati, President Director, Pt. Kalbe Genexine Biologics
Anand Gautam, Senior Director And Head, External Science And Innovation, Anz And Sea, Pfizer
Petcha Kucha
Biotech Inve$t
15:30

Biotech Pitch

10 minutes per company
James Garner, Chief Executive Officer And Managing Director, Kazia Therapeutics Limited
T Balganesh, President, GangaGen
Wenzhi Tian, Chief Executive Officer, ImmuneOnco Biopharma
16:30

End of Phar-East 2019

last published: 17/Jan/19 09:15

* 活動內容有可能不事先告知作更動及調整。